GHX
Global Healthcare Exchange (GHX ), a leader in cloud-based healthcare supply chain management solutions, today announced that it has entered into an agreement to acquire a majority of the assets and employees of Germany-based Medical Columbus AG , a provider of healthcare procurement software for providers and suppliers across Germany, Switzerland, Austria, Luxembourg, and the Netherlands. The acquisition expands GHX’s European supply chain and procurement products portfolio to deliver even greater efficiency and value to the healthcare community. The acquisition is expected to close in about three months.
Both companies’ solutions serve providers, suppliers and group purchasing organizations (GPOs) in healthcare. The combined product offering gives GHX the ability to expand its procurement solutions offering and its trading partner network in key markets in Europe while helping to deliver operational efficiencies for both providers and suppliers in Germany, Switzerland, Austria, Luxembourg and the Netherlands. GHX has been operating in Europe since 2000.
“The solutions and employee team we are acquiring is a tremendous addition to GHX Europe,” said Bruce Johnson, CEO and president of GHX. “With this acquisition, we are enhancing our solutions portfolio and expanding our footprint in Europe. This is great for our multi-national suppliers and local European provider customers by providing them with a larger pool of potential trading partners that can fuel increased business process efficiencies.”
Added Dirk Isenberg, CEO at Medical Columbus, “We are pleased to be joining with GHX to help drive down costs in healthcare, allowing our customers access to best of breed e-catalogue and e-procurement solutions.”
With more than 4,000 hospitals and 18,000 provider facilities worldwide in the GHX community, the acquisition reinforces GHX’s commitment to remove cost from healthcare by continuing to grow a global trading partner network that benefits both provider and suppliers.
ABOUT MEDICAL COLUMBUS
Founded in 1998, Medical Columbus is one of the e-health pioneers focusing on procurement processes. The company's transaction platform synchronizes the various IT systems and catalog data from medical device, pharmaceutical industry, and hospital customers. By standardizing data and processes, mistakes are avoided, processing times are shortened, and costs for suppliers and providers are significantly reduced. Medical Columbus products are best of breed in modern healthcare supply chain solutions. For more information, visit www.medicalcolumbus.de .
ABOUT GHX EU
Global Healthcare Exchange, LLC (GHX) is a healthcare and data automation company, empowering healthcare organizations to enable better patient care and maximize savings using its world-class cloud-based supply chain technology platform, solutions, analytics and services. GHX brings together healthcare providers, manufacturers and distributors in North America, and Europe, who rely on smart, secure healthcare-focused technology and comprehensive data to automate business processes and make more informed, timely and fact-based decisions. Solutions span procurement and accounts payable automation, contract and inventory management, vendor credentialing and management, business intelligence, payment management and other supply chain-related tools and services. For more information, visit www.ghx.com/europe/en (Europe), www.ghx.com (North America), and The Healthcare Hub blog.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710006040/en/
Contact:
GHX Europe:
4iMedia
Viktoria
Skrzypek, +49 (0) 341 870 98 4-38
Viktoria.Skrzypek@4iMEDIA.com
or
GHX
North America:
Tier One Partners
Kathy Wilson,
781-652-0499
kwilson@tieronepr.com
or
Medical
Columbus:
Dirk Isenberg, +49 (0) 6174 9617 18
Dirk.isenberg@medicalcolumbus.de
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Raises the Bar for Workforce Development With State-of-the-Art Career & Learning Center23.4.2025 22:00:00 CEST | Press release
Textron Aviation Inc. a Textron Inc. (NYSE: TXT) company, today announced its new Career & Learning Center is complete and fully operational serving prospective, current and future Textron Aviation employees. Strategically located on the company’s East Wichita Campus, this state-of-the-art facility expands the training footprint to more than 75,000 square feet and provides a world-class employee experience during the application, hiring, onboarding and training processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423874476/en/ Textron Aviation Career and Learning Center | Textron Aviation “The Textron Aviation Career & Learning Center is an important investment in building the next generation of aviation manufacturing, support and professional talent,” said Ron Draper, president and CEO. “Recruiting, hiring and training a world-class workforce is vital to our ability to provide the best aviation experience for our cu
TSMC Unveils Next-Generation A14 Process at North America Technology Symposium23.4.2025 20:40:00 CEST | Press release
Showcasing TSMC’s latest offerings for high performance computing, smartphone, automotive, and IoT applications TSMC (TWSE: 2330, NYSE: TSM) today unveiled its next cutting-edge logic process technology, A14, at the Company’s North America Technology Symposium. Representing a significant advancement from TSMC’s industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Planned to enter production in 2028, the current A14 development is progressing smoothly with yield performance ahead of schedule. Compared with the N2 process, which is about to enter volume production later this year, A14 will offer up to 15% speed improvement at the same power, or up to 30% power reduction at the same speed, along with more than 20% increase in logic density. Leveraging the Company’s experience in design-tech
Veracode Delivers End-to-End Risk Coverage with New Tools: AI-Powered Dynamic Analysis Security Testing with External Attack Surface Management23.4.2025 17:42:00 CEST | Press release
Seamless Integration and Speed: Latest Innovations Empower Faster, Smarter, and Safer Software Security Veracode, a global leader in application risk management, today announced new capabilities to help organizations address emerging threats, giving security professionals better visibility and control in one place. The launch includes new AI-powered functionality in the Dynamic Application Security Testing (DAST)product and an External Attack Surface Management (EASM) capability. Together, they enable security teams to discover their entire attack surface and prioritize the most critical risk to streamline and simplify security scanning. “Security teams need to see and secure everything; not only what is inside their perimeter,” said Derek Maki, Head of Product at Veracode. “With our latest DAST capabilities and Application Risk Management platform enhancements, we’re helping organizations shift from vulnerability scanning to holistic risk management, to better identify risk residing i
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting23.4.2025 17:03:00 CEST | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago. “The data featured at the 2025 ASCO Annual Meeting, from both our approved medicines and early-stage pipeline, reflect our ongoing efforts to transform cancer care,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We are advancing potential therapies across some of the most difficult-to-treat cancers and hematological diseases, including squamous cell anal cancer, ovarian cancer and myelofibrosis, with the hope of making a meaningful difference for these patients.” Key abstracts accepted for presentation: Oral Presentations INCB123667 Safety and Preliminary Efficacy from a Phase 1 Study of INCB123667, a Selective CDK2 Inhibitor, in Patients with Advanced Platinum-Resistant and Refractory Ovarian Cancer (OC) (Abst
LTIMindtree’s FY25 Revenue up 7% in INR23.4.2025 16:42:00 CEST | Press release
Order Inflow at USD 6 Billion, up 6% on full-year basis LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the fourth quarter and full year ended Mar 31, 2025, as approved by its Board of Directors. “We concluded FY25 with a revenue growth of 5% in constant currency terms and an EBIT margin of 14.5%. Our key verticals and a major geography drove our yearly growth despite an ongoing challenging macro environment. The robust order inflow, driven by a significant array of AI-led deal wins, illustrates the pervasive integration of AI across our service offerings. Venu Lambu’s transition to LTIMindtree has been seamless and supports our strategic goals. His growing understanding of the organisation, combined with our ability to secure large deals, strong presence in tech-intensive sectors, and robust balance sheet, positions us well to leverage the opportunities ahead of us.” - Debashis Chatterjee,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom